Rapid Electrical Impedance Spectroscopy for Detection of High-Frequency Irreversible Electroporation Ablation Growth in a Rodent Glioma Model
Rapid Electrical Impedance Spectroscopy for Detection of High-Frequency Irreversible Electroporation Ablation Growth in a Rodent Glioma Model
批准号:
10310562
负责人:
Waldemar Debinski
金额:
$14.18万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-17 至 2023-07-31
关键词:
AblationAddressAdjuvantAmericanBioluminescenceBlood - brain barrier anatomyBrain NeoplasmsBypassCanis familiarisCardiacCathetersCell DeathCell NucleusCell membraneCellsCerebrumComplexConvectionCyclophosphamideDefectDetectionDevelopmentDiagnosisDiffusionDrug Delivery SystemsElectrodesElectroporationElectroporation TherapyExcisionExposure toFocused UltrasoundFourier AnalysisFrequenciesGeneral AnesthesiaGenerationsGeneticGlioblastomaGliomaGrantGrowthHepaticHeterogeneityHourImageInfusion proceduresInvadedInvestigationKarnofsky Performance StatusKidneyKnowledgeLesionMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of brainMeasurementMediatingMicrobubblesMicroscopicModalityModelingMolecularMonitorMuscleMuscle ContractionNecrosisNeedlesNervePancreasParalysedParentsPatientsPerformancePharmaceutical PreparationsPhysiologic pulsePilot ProjectsPostoperative PeriodPrognosisProstateProteinsRadiationRecoveryRefluxReproducibilityRodentSolidSolid NeoplasmSpectrum AnalysisSurvival RateTechniquesTechnologyTherapeuticTissuesTumor TissueUltrasonographybaseblood-brain barrier disruptionblood-brain barrier permeabilizationbrain parenchymacancer cellchemotherapyclinically relevantcombinatorialelectric fieldelectric impedanceimprovedmigrationnanoparticlenanoscaleneoplasticnoveloccludinparent grantpreclinical studypressurestandard of caretemozolomidetreatment strategytumortumor ablationtumor heterogeneityvoltage
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Diversity Supplement Project Summary
The most common and aggressive malignant brain tumor, glioblastoma multiforme (GBM), demonstrates a 5-
year survival rate of only 5.6%. Difficulties arising in the treatment of GBM include the inability of large molecular
agents to permeate through the blood-brain barrier (BBB); migration of highly invasive GBM cells beyond the
solid/visible tumor margin; and gross, microscopic, and genetic intratumor heterogeneity. To circumvent issues
associated with standard of care and to improve the versatility of electroporation-based therapies for intracranial
applications, our group has developed a novel tumor ablation strategy which utilizes bursts of bipolar PEFs to
nonthermally ablate tumors. This second-generation strategy, termed high-frequency IRE (H-FIRE),
demonstrates focal tissue ablation with a surrounding zone of BBB disruption (BBBD) that extends centimeters
beyond the nonthermal lesion. Despite major progress in development of electroporation-based nonthermal
ablation therapies, several challenges and gaps in knowledge exist. The determination of an ablation/pulsing
endpoint is not currently defined and is reliant on postoperative imaging with MRI and ultrasound techniques.
Therefore, building off the parent P01 grant, this Diversity Supplement proposal seeks to conduct a preliminary
investigation of H-FIRE and the proposed Fourier Analysis SpecTroscopy to ablate neoplastic tissue in an
orthotopic rodent GBM tumor model and determine a pulsing endpoint. This project proposal has 2 specific aims:
Specific Aim 1: Preliminary investigation of FAST impedance measurements to determine a pulsing
endpoint for H-FIRE ablation. H-FIRE therapy will be applied to ablate GBM tumor tissue in an orthotopic
rodent GBM tumor model. It is known that the H-FIRE ablation volume reaches a saturation following a set
number of bursts applied. Therefore, we will utilize the newly developed Fourier Analysis SpecTroscopy, a rapid
electrical impedance spectroscopy technique, to continually monitor changes in tissue impedance throughout H-
FIRE therapy. Specific Aim 2: Preliminary investigation of combinatorial H-FIRE therapy with QUAD-CTX.
This pilot study will elucidate the effects of a molecular adjuvant to enhance glioma treatment with H-FIRE. H-
FIRE-mediated BBB disruption facilitates enhanced drug delivery to infiltrative glioma cells invading healthy brain
parenchyma. An F98 rodent glioma model, similar to that of Aim 2, will be employed. H-FIRE therapy will be
administered and bioluminescent imaging used to quantify the tumor bioluminescence follow stand-alone H-
FIRE therapy and combinatorial H-FIRE with newly developed QUAD-CTX.
期刊论文(31)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Controlled Catheter Movement Affects Dye Dispersal Volume in Agarose Gel Brain Phantoms.
受控导管运动影响琼脂糖凝胶脑模型中的染料分散量。
DOI:
10.3390/pharmaceutics12080753
发表时间:
2020
期刊:
Pharmaceutics
影响因子:
5.4
作者:
[Mehta,JasonN, McRoberts,GabrielleR, Rylander,ChristopherG]
通讯作者:
Rylander,ChristopherG
DOI:
10.34133/2019/8081315
发表时间:
2019-01-01
期刊:
RESEARCH
影响因子:
11
作者:
[Ivey, J. W., Wasson, E. M., Verbridge, S. S.]
通讯作者:
Verbridge, S. S.
DOI:
10.1016/j.rvsc.2021.12.018
发表时间:
2022-03
期刊:
Research in veterinary science
影响因子:
2.4
作者:
[Kani Y, Hinckley J, Robertson JL, Mehta JM, Rylander CG, Rossmeisl JH]
通讯作者:
Rossmeisl JH
DOI:
10.1038/s41598-021-87228-5
发表时间:
2021-04-07
期刊:
Scientific reports
影响因子:
4.6
作者:
[Hendricks-Wenger A, Aycock KN, Nagai-Singer MA, Coutermarsh-Ott S, Lorenzo MF, Gannon J, Uh K, Farrell K, Beitel-White N, Brock RM, Simon A, Morrison HA, Tuohy J, Clark-Deener S, Vlaisavljevich E, Davalos RV, Lee K, Allen IC]
通讯作者:
Allen IC
DOI:
10.3389/fonc.2023.1171278
发表时间:
2023
期刊:
FRONTIERS IN ONCOLOGY
影响因子:
4.7
作者:
[Campelo, Sabrina N., Lorenzo, Melvin F., Partridge, Brittanie, Alinezhadbalalami, Nastaran, Kani, Yukitaka, Garcia, Josefa, Saunier, Sofie, Thomas, Sean C., Hinckley, Jonathan, Verbridge, Scott S., Davalos, Rafael V., Rossmeisl Jr, John H. H.]
通讯作者:
Rossmeisl Jr, John H. H.
共 22 条
Combinatorial Immunotherapy using a Multivalent Drug Conjugate for GBM Treatment
-
批准号:10560392
-
项目类别:
-
资助金额:$59.47万
-
财政年份:2022
-
负责人:Waldemar Debinski
-
依托单位:
Multi-receptor Targeting of Glioblastoma
-
批准号:10693378
-
项目类别:
-
资助金额:$61.57万
-
财政年份:2021
-
负责人:Waldemar Debinski
-
依托单位:
Multi-receptor Targeting of Glioblastoma
-
批准号:10313101
-
项目类别:
-
资助金额:$64.28万
-
财政年份:2021
-
负责人:Waldemar Debinski
-
依托单位:
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBM
-
批准号:10220881
-
项目类别:
-
资助金额:$39.98万
-
财政年份:2017
-
负责人:Waldemar Debinski
-
依托单位:
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBM
-
批准号:10493966
-
项目类别:
-
资助金额:$14.18万
-
财政年份:2017
-
负责人:Waldemar Debinski
-
依托单位:
Maximizing Local Access to Therapeutic Deliveries in Glioblastoma
-
批准号:9978729
-
项目类别:
-
资助金额:$167.11万
-
财政年份:2017
-
负责人:Waldemar Debinski
-
依托单位:
Sub-component for Institution # 16-01848 Core 1 - Administrative
-
批准号:10220885
-
项目类别:
-
资助金额:$12.55万
-
财政年份:2017
-
负责人:Waldemar Debinski
-
依托单位:
Maximizing Local Access to Therapeutic Deliveries in Glioblastoma
-
批准号:10220880
-
项目类别:
-
资助金额:$182.74万
-
财政年份:2017
-
负责人:Waldemar Debinski
-
依托单位:
Molecular Combinatorial Therapy of Glioblastoma Multiforme
-
批准号:8010645
-
项目类别:
-
资助金额:$30.92万
-
财政年份:2010
-
负责人:Waldemar Debinski
-
依托单位:
Molecular Combinatorial Therapy of Glioblastoma Multiforme
-
批准号:8385587
-
项目类别:
-
资助金额:$28.14万
-
财政年份:2010
-
负责人:Waldemar Debinski
-
依托单位:
Molecular Combinatorial Therapy of Glioblastoma Multiforme
-
批准号:7782615
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2010
-
负责人:Waldemar Debinski
-
依托单位:
Molecular Combinatorial Therapy of Glioblastoma Multiforme
-
批准号:8588249
-
项目类别:
-
资助金额:$29.04万
-
财政年份:2010
-
负责人:Waldemar Debinski
-
依托单位:
Molecular Combinatorial Therapy of Glioblastoma Multiforme
-
批准号:8196907
-
项目类别:
-
资助金额:$30.1万
-
财政年份:2010
-
负责人:Waldemar Debinski
-
依托单位:
Ephrins and Cancer
-
批准号:7279277
-
项目类别:
-
资助金额:$0.9万
-
财政年份:2006
-
负责人:Waldemar Debinski
-
依托单位:
Ephrins and Cancer
-
批准号:7799816
-
项目类别:
-
资助金额:$0.9万
-
财政年份:2006
-
负责人:Waldemar Debinski
-
依托单位:
Ephrins and Cancer
-
批准号:7567457
-
项目类别:
-
资助金额:$0.9万
-
财政年份:2006
-
负责人:Waldemar Debinski
-
依托单位:
Molecular Requirements for Recombinant Cytotoxins Efficacy
-
批准号:7535512
-
项目类别:
-
资助金额:$24.38万
-
财政年份:2005
-
负责人:Waldemar Debinski
-
依托单位:
Molecular Requirements for Recombinant Cytotoxins Efficacy
-
批准号:7163020
-
项目类别:
-
资助金额:$24.38万
-
财政年份:2005
-
负责人:Waldemar Debinski
-
依托单位:
Molecular Requirements for Recombinant Cytotoxins Efficacy
-
批准号:7019061
-
项目类别:
-
资助金额:$25.11万
-
财政年份:2005
-
负责人:Waldemar Debinski
-
依托单位:
Molecular Requirements for Recombinant Cytotoxins Efficacy
-
批准号:7322815
-
项目类别:
-
资助金额:$24.38万
-
财政年份:2005
-
负责人:Waldemar Debinski
-
依托单位:
海外基金